High purity isolation of low density neutrophils casts doubt on their exceptionality in health and disease GR Hardisty, F Llanwarne, D Minns, JL Gillan, DJ Davidson, ... Frontiers in Immunology 12, 625922, 2021 | 35 | 2021 |
Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages JL Gillan, DJ Davidson, RD Gray European Respiratory Journal 57 (6), 2021 | 20 | 2021 |
CAGE sequencing reveals CFTR-dependent dysregulation of type I IFN signaling in activated cystic fibrosis macrophages JL Gillan, M Chokshi, GR Hardisty, S Clohisey Hendry, ... Science Advances 9 (21), eadg5128, 2023 | 4 | 2023 |
Macrophages from gut-corrected CF mice express human CFTR and lack a pro-inflammatory phenotype JL Gillan, GR Hardisty, DJ Davidson, RD Gray Journal of Cystic Fibrosis 21 (2), 370-374, 2022 | 2 | 2022 |
WS08-1 Calprotectin: the cystic fibrosis antigen regulates neutrophil migration during experimental lung inflammation and is a novel therapeutic target in cystic fibrosis G Hardisty, S Law, J Gillan, EG Findlay, S Vermeren, D Davidson, R Gray Journal of Cystic Fibrosis 18, S14, 2019 | 2 | 2019 |
Neutrophil extracellular traps are associated with airways inflammation and increased severity of lung disease in Cystic Fibrosis S Law, G Hardisty, JL Gillan, NJ Robinson, DJ Davidson, MKB Whyte, ... ERJ Open Research, 2024 | | 2024 |
Nasal cathelicidin is expressed in early life and is increased during mild, but not severe respiratory syncytial virus infection S Sintoris, JM Binkowska, JL Gillan, RP Zuurbier, J Twynam-Perkins, ... Scientific Reports 14 (1), 13928, 2024 | | 2024 |
443 Elexacaftor/tezacaftor/ivacaftor treatment promotes inflammation resolution in people with cystic fibrosis N Robinson, G Hardisty, J Gillan, R Gray Journal of Cystic Fibrosis 21, S253-S254, 2022 | | 2022 |
Macrophage dysfunction in Cystic fibrosis lung disease J Gillan The University of Edinburgh, 2021 | | 2021 |
349: Tezacaftor/ivacaftor improves clinical outcomes but has only modest effects on inflammation in CF N Robinson, G Hardisty, J Gillan, R Gray Journal of Cystic Fibrosis 20, S167, 2021 | | 2021 |
350: Elexacaftor-tezacaftor-ivacaftor treatment fundamentally changes the inflammatory landscape in people with CF G Hardisty, N Robinson, J Gillan, L Hunt, R Gray Journal of Cystic Fibrosis 20, S167, 2021 | | 2021 |
WS12. 4 Tezacaftor/ivacaftor therapy induces increased airway neutrophilia and circulating neutrophil activation in cystic fibrosis GR Hardisty, NJ Robinson, JL Gillan, RD Gray Journal of Cystic Fibrosis 19, S20, 2020 | | 2020 |
ePS3. 03 Probing the central role of macrophages in cystic fibrosis inflammation JL Gillan, GR Hardisty, NJ Robinson, RD Gray Journal of Cystic Fibrosis 19, S43, 2020 | | 2020 |
CF ANTIGEN AS A THERAPEUTIC TARGET IN LUNG INFLAMMATION G Hardisty, S Law, J Gillan, GE Findlay, RD Gray PEDIATRIC PULMONOLOGY 54, S431-S432, 2019 | | 2019 |
s100A9 regulates neutrophil migration during experimental lung inflammation and is a novel therapeutic target in respiratory disease G Hardisty, S Law, J Gillan, EG Findlay, S Vermeren, D Davidson, R Gray EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 49, 70-71, 2019 | | 2019 |
Neutrophil extracellular traps are elevated in Cystic Fibrosis sputum and associated with neutrophilic inflammation and lung function decline SMP Law, G Hardisty, J Gillan, I Dransfield, RD Gray | | |